SCHEMBL1917217

SCHEMBL1917217

COc1[c]cccc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
ALDH1A1 P00352 8/20 0.43
ALOX15 P16050 1/20 0.43
KDM4E B2RXH2 7/20 0.41
HPGD P15428 6/20 0.41
HSD17B10 Q99714 4/20 0.41
CDC25B P30305 3/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 3/20 0.39
HMGB1 P09429 2/20 0.39
NAPRT Q6XQN6 2/20 0.39
ESR1 P03372 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
TSHR P16473 1/20 0.39
GGT1 P19440 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10652894 0.83 TSHR (0.48) ALDH1A1ALOX15KDM4EHSD17B10KMT2A
SCHEMBL3929070 0.83 PARP1 (0.41) HTTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3503701 0.80 LMNA (0.43) HTTALDH1A1ALOX15KDM4EHPGD
SCHEMBL7387055 0.80 HMGCR (0.41) ALDH1A1KDM4EHPGDKMT2AUSP2
SCHEMBL3505181 0.78 ALDH1A1 (0.45) HTTALDH1A1ALOX15KDM4EHPGD
SCHEMBL23039128 0.78 L3MBTL1 (0.44) HTTALDH1A1KDM4EHPGDKMT2A
SCHEMBL5132767 0.78 TSHR (0.58) HTTALDH1A1ALOX15KDM4EHPGD
SCHEMBL20797165 0.76 LMNA (0.46) HTTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6718464 0.76 CA1 (0.41) HTTALDH1A1ALOX15KDM4EHPGD
SCHEMBL826011 0.75 ALDH1A1 (0.38) ALDH1A1ALOX15KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US claimed
EP-2090571-B1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation BOEHRINGER INGELHEIM PHARMA (DE) 2012-05-16 EP claimed
EP-2332924-A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-06-15 EP claimed
JP-4460292-B2 2010-05-12 JP claimed
US-7709480-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-04 US claimed
EP-1438053-B1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME BOEHRINGER INGELHEIM PHARMA (DE) 2008-09-10 EP claimed
US-7173028-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-06 US claimed
US-20060100211-A1 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-05-11 US claimed
JP-2005509624-A 2005-04-14 JP claimed
EP-1438053-A1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-21 EP claimed
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-09-11 US claimed
WO-2003032997-A1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 WO claimed
WO-2000024725-A1 PENTACYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HEPATITIS C VIRUS NS3 HELICASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-05-04 WO claimed
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-02 US disclosed
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-08 US disclosed
CN-110317328-A The preparation method of polyarylate of the one kind based on 2- (4- carboxyl -3- methoxyphenyl) -5- pyridone and imidazoles 浙江甬仑聚嘉新材料有限公司 2019-10-11 CN disclosed
US-4098758-A ORGANIC ACIDS, FOR USE IN POLYMER SYSTEMS KENRICH PETROCHEMICALS, INC. (US) 1978-07-04 US disclosed
US-4096110-A Filled polyesters containing organic titanate esters KENRICH PETROCHEMICALS, INC. (US) 1978-06-20 US disclosed
US-4094853-A Alkoxy titanate salts useful as coupling agents KENRICH PETROCHEMICALS, INC. (US) 1978-06-13 US disclosed
US-4087402-A USED FOR TREATMENT OF INORGANIC FILLERS KENRICH PETROCHEMICALS, INC. (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases BMP1, DPEP1, MEP1A HTT 2952/4885ALDH1A1 2800/4885ALOX15 979/4885
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF CYP2C19, CYP3A7, CYP3A5 HTT 2225/4885ALDH1A1 1200/4885ALOX15 3298/4885
US-20060100211-A1 Pyrimidine derivatives TYMP, TYMS, DPYD HTT 3317/4885ALDH1A1 252/4885ALOX15 1772/4885
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF CYP2C19, CYP3A7, CYP3A5 HTT 2225/4885ALDH1A1 1200/4885ALOX15 3298/4885
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases COL1A1, MKI67, INSR HTT 4543/4885ALDH1A1 605/4885ALOX15 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.